Phase 2 randomised trial in 189 patients with resistant hypertension: monthly XXB750 (30-240 mg) did not lower 24-hour systolic BP vs placebo at 12 weeks despite dose-dependent cGMP rises; adverse events were numerically higher.
RCTn = 189
White et al. Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension: A Randomized Phase 2 Trial